That level of weight stability is remarkable compared to most weight loss interventions where regain begins almost immediately after plateau
Haas sit down with Josh Holyfield fitness coach, educator, and one of the most straightforward voices in the peptide and optimization space
Multi-indication label expansion: Semaglutide approved across obesity, cardiovascular risk reduction, MASH, and sleep apnea creates a total addressable patient population of approximately 640 million globally nearly four times the obesity-only base adding new prescriber populations including cardiologists, hepatologists, and sleep medicine specialists
El Bekay R, Con-Aragez L, Fernndez-Garca D, Oliva-Olivera W, Bernal-Lpez R, Clemente-Postigo M, Delgado-Lista J, Diaz-Ruiz A, Guzman-Ruiz R, Vzquez-Martnez R, et al: Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
Rubio, G
The largest markets for GLP-1 weight loss drugs like Ozempic and Zepbound today are the worlds richest countries